Genetic variation in UDP-glucuronosyltransferase 1A1 (UGT1A1) expression has several important clinical implications. UGT1A1 basal transcription is affected by a polymorphic (TA) n repeat, and another important regulatory element is the phenobarbital-responsive enhancer module (PBREM) which might contain variants affecting inducible gene expression. We assessed the extent of linkage disequilibrium between the (TA) n polymorphism and variants in the PBREM and UGT1A1 promoter. We also investigated the relationship between PBREM-(TA) n haplotypes and the glucuronidation rate of the UGT1A1 substrate SN-38. DNAs from 83 human livers were genotyped for the (TA) n polymorphism and microsomes from the same livers were phenotyped for SN-38 glucuronidation. The (TA) n polymorphism was genotyped in 24 additional African-Americans included in the Human Variation Panel (Coriell Institute). A 606-bp region spanning the PBREM was sequenced in 81 liver and a subset of 22 Human Variation Panel DNAs and six variants were found. The 23279G>T and 23156G>A variants are common (0.39 and 0.30, respectively). 23279G>T is more common in Caucasians than AfricanAmericans (P 0.001). In Caucasians, linkage disequilibrium was highly significant between sites 23279, 23156, and the (TA) n polymorphism (P < 0.0001). In contrast, in African-Americans, only marginal levels of significance were observed between (TA) n and 23279 (P 0.02) and between 23279 and 23156 (P 0.04). Ten promoter haplotypes were identified. Haplotype I is the most common (0.39), from which haplotype II (0.15) differs at position 23279. SN-38G formation rates were correlated with (TA) n genotypes. This study showed that (i) common promoter variants are in linkage disequilibrium and (ii) the haplotype structure of UGT1A1 promoter is probably different between Caucasians and African-Americans.
Genetic variation in UDP-glucuronosyltransferase 1A1 (UGT1A1) expression has several important clinical implications. UGT1A1 basal transcription is affected by a polymorphic (TA) n repeat, and another important regulatory element is the phenobarbital-responsive enhancer module (PBREM) which might contain variants affecting inducible gene expression. We assessed the extent of linkage disequilibrium between the (TA) n polymorphism and variants in the PBREM and UGT1A1 promoter. We also investigated the relationship between PBREM-(TA) n haplotypes and the glucuronidation rate of the UGT1A1 substrate SN-38. DNAs from 83 human livers were genotyped for the (TA) n polymorphism and microsomes from the same livers were phenotyped for SN-38 glucuronidation. The (TA) n polymorphism was genotyped in 24 additional African-Americans included in the Human Variation Panel (Coriell Institute). A 606-bp region spanning the PBREM was sequenced in 81 liver and a subset of 22 Human Variation Panel DNAs and six variants were found. The 23279G>T and 23156G>A variants are common (0.39 and 0.30, respectively). 23279G>T is more common in Caucasians than AfricanAmericans (P 0.001). In Caucasians, linkage disequilibrium was highly significant between sites 23279, 23156, and the (TA) n polymorphism (P < 0.0001). In contrast, in African-Americans, only marginal levels of significance were observed between (TA) n and 23279 (P 0.02) and between 23279 and 23156 (P 0.04). Ten promoter haplotypes were identified. Haplotype I is the most common (0.39), from which haplotype II (0.15) differs at position 23279. SN-38G formation rates were correlated with (TA) n genotypes. This study showed that (i) common promoter variants are in linkage disequilibrium and (ii) the haplotype structure of UGT1A1 promoter is probably different between Caucasians and African-Americans. 
Introduction
Glucuronidation plays a major role in the pharmacological activity and clearance of a large variety of compounds [1] . Genetic studies of UGTs aim to characterize an individual's predisposition to various diseases and increased risk of adverse outcome to drug treatment. The variation in the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene is the most extensively studied. UGT1A1 basal expression is affected by the variable number of TA repeats in the TATA box. Larger TA number is associated with reduced transcriptional activity [2] , leading to various degrees of impaired glucuronidation of UGT1A1 substrates. Homozygosity for (TA) 7 allele is associated with Gilbert's syndrome (a familial mild hyperbilirubinemia) [3, 4] and predisposition to the toxic effects of cancer treatment with irinotecan [5, 6] . Increased risk of breast cancer was reported in African-American women who carried the (TA) 7 and (TA) 8 alleles [7] . In addition to the TATA box, Sugatani et al. [8] identified a region in the UGT1A1 promoter approximately 3 kb upstream of the TATA box that regulates UGT1A1 inducibility by phenobarbital. It is also hypothesized that this phenobarbital-responsive enhancer module (PBREM) might be modulated by endogenous factors [9] . UGT1A1 activity is probably the result of PBREM-dependent modulation of TATA box-dependent basal expression.
Polymorphisms in UGT1A1 are relevant to the treatment of cancer patients with irinotecan. SN-38 is its active metabolite, and SN-38 glucuronidation represents a mechanism to protect patients from the toxic effects of irinotecan [10] . Reduced SN-38 glucuronidation is thought to underlie the severe toxicity associated with irinotecan treatment in some patients [10] . Due to the clinical implications of genetically modified regula-tion of UGT1A1 activity, we sequenced the PBREM and genotyped the polymorphisms in the TATA box of the UGT1A1 promoter. We also aimed to evaluate interethnic differences in allele frequencies and extent of linkage disequilibrium due to the observed differences in total bilirubin levels between Caucasians and African-Americans [2] .
We describe the extent of linkage disequilibrium between newly and previously described promoter variants in Caucasians and African-Americans, the structure of promoter haplotypes, and the correlation between genotypes or haplotypes and SN-38 glucuronidation rates.
Materials and methods

Chemicals and reagents
Exonuclease I and shrimp alkaline phosphatase (exo/ SAP) was purchased from USB (Cleveland, Ohio, USA). ABI Big Dye terminator cycle-sequencing kit was purchased from Applied Biosystems (Foster City, California, USA). Primers for amplification, sequencing of the PBREM, and amplification of the (TA) n polymorphism were obtained from GibcoBRL (Invitrogen Co., Carlsbad, California, USA). SN-38 was kindly provided by Dr Kiyoshi Terada (Yakult Honsha Co., Ltd, Japan). Camptothecin, UDPGA, magnesium chloride, trizma base, potassium monohydrogen phosphate and 1-heptanesulfonic acid were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Acetonitrile, tetrahydrofuran and hydrochloric acid were obtained from Fisher Scientific (Hanover, Illinois, USA).
Human livers
Normal human livers (n ¼ 83) were mainly obtained from Liver Tissue Procurement and Distribution System (National Institutes of Diabetes and Digestive and Kidney Diseases, Minneapolis, Minnesota). DNA was isolated by using Qiagen RNA/DNA Maxi Kit (Qiagen Inc., Valencia, California, USA), and microsomes were isolated following differential centrifugation methods [11] . DNA and microsomes were provided by the Liver Core Bank Facility (director, Dr Mary Relling, St. Jude Children's Research Hospital) of the Pharmacogenetics of Anticancer Agents Research (PAAR) Group. In order to identify livers in which enzyme degradation occurred, we looked for liver samples consistently comprised in the 10th percentile of UGT1A1, UGT1A9 and UGT2B7 activities. UGT1A9 and UGT2B7 activities were measured using specific probes (data not shown) [12, 13] . Out of eight samples within the 10th percentile of UGT1A1, only one sample was comprised within the 10th percentile of activities of the other two enzyme activities. If different handling/storage of the liver or microsomal protein degradation occurred in that sample, this should not have affected the degree of phenotype/genotype correlation because the individual had a 7/7 genotype, and among the 7/7 genotype samples (n ¼ 11), it had the 4th lower value. Moreover, lack of correlation between UGT1A1 and UGT2B7 activities (n ¼ 83, r ¼ 0.07, P ¼ 0.5) shows that differences in tissue integrity and microsome stability have probably a mild influence (if any) on the UGT phenotype.
The ethnic composition of the 83 liver donors comprised: Caucasians 68%, African-Americans 18%, Asians 1%, others 2%. The percentage of samples of unknown ethnic origin was 12%.
Genotyping of (TA) n polymorphism
In order to genotype the (TA) n polymorphism, approximately 40 ng of DNA was subjected to amplification by polymerase chain reaction (PCR). The amplification primers used have been previously described [4] , where the sequence of the forward primer is 59-GTCACGT GACACAGTCAAAC-39 and that of the reverse primer is 59-TTTGCTCCTGCCAGAGGTT-39. These primers flank the polymorphic TA locus in the promoter region of the UGT1A1 gene and amplify a 98 bp fragment when a (TA) 6 allele is present and a 100 bp fragment when a (TA) 7 allele is present. In the presence of (TA) 5 and (TA) 8 alleles, 96 bp and 102 bp alleles are amplified. The reverse primer is labelled with a fluorescent dye at its 59-end to permit visualization of the amplification product. The amplification reactions were performed in a 10 ìl volume consisting of 1.5 mmol MgCl 2 , 250 mmol dNTPs, 0.8 mmol of each primer and 0.5 U of Taq polymerase (Amplitaq Gold from Applied Biosystems). The polymerase was activated at 95 8C for 10 min and DNA amplified for 35 cycles at 95 8C for 30 s, 55 8C for 30 s and 72 8C for 30 s, followed by a final extension at 72 8C for 10 min. Control DNAs from individuals known to have a 6/6, 6/7 and 7/7 genotype were included in the PCR analysis. PCR fragments were subjected to gel electrophoresis on an ABI 377 DNA analyser (Applied Biosystems). Amplified products were diluted in a formamide and dextran blue loading buffer and 1 ìl combined with 1 ìl of size standard (GS-350 from Applied Biosystems), denatured at 95 8C, and loaded onto a 6% denaturing polyacrylamide gel. Electrophoresis was performed for 3.5 h following manufacturers recommendations. The Genescan and Genotyper software (version 3.7, Applied Biosystems) was used to analyse fragments for size determination.
Sequencing of PBREM
A 606 bp region (À3641 to À3036) including PBREM ( Fig. 1 is that deposited in the GenBank database (accession number AF313454). Amplification of the PCR product was performed in a 10 or 25-ìl reaction volume using the following primers: 59-CTGGGGA TAAACATGGGATG-39 (forward) and 59-CACCAC CACTTCTGGAACCT-39 (reverse). These primers were designed using Primer3 [14] . PCR conditions were 2 min at 94 8C, 32 or 33 cycles of a three-step cycling program (30 s at 94 8C, 30 s at 66.8 8C and 1 min at 72 8C) and 72 8C for 3 min. Following exo/SAP cleanup of the PCR product, this amplicon was then sequenced in the forward and reverse directions using the amplification primers, Big Dye terminator chemistry, and run on an ABI 3700 (Applied Biosystems) following the manufacturer's protocol. Sequences were analysed and individuals genotyped using the PolyPhred software [15] . To determine the ancestral state of the polymorphisms found in humans, we compared the sequence to that of baboon (accession number AC091778).
SN-38 glucuronidation assay in human liver microsomes
Samples were phenotyped by using SN-38 as a substrate for UGT1A1. The incubation mixture consisted of 5 ìmol SN-38, 10 mmol MgCl 2 , 1 mg/ml microsomes, 0.025 mol Tris-HCl (pH 7.4) and 5 mmol UDP-GA. Samples were incubated for 30 min at 37 8C. The reaction was stopped by the addition of methanol. These conditions were selected after previous optimization of the enzyme reaction [16] . Camptothecin (75 ng) was used as an internal standard. SN-38 glucuronidation was measured by HPLC (Hitachi Instruments Inc., San Jose, California, USA) with fluorescence detection (º excitation ¼ 355 nm, º emission ¼ 515 nm). A ìBondapak TM C 18 column (3.9 3 300 mm, 10 ìm; Waters Corp., Milford, Massachusetts, USA) and ìBondapak TM C 18 guardpak (Waters Corp.) were used. A mobile phase of 8/4/88 acetonitrile/tetrahydrofuran/0.9 mmol sodium heptanesulfonic acid in 50 mmol potassium dihydrogen phosphate (pH 4) was used during the first 7 min of the run. From 7.1-25 min, the eluent consisted of 30/70 acetonitrile/ 5 mmol sodium heptanesulfonic acid in 50 mmol potassium dihydrogen phosphate (pH 4). The flow rate was 0.9 ml/min. Retention times for SN-38G, SN-38 and camptothecin were 13.3, 18.4 and 19.3 min, respectively. SN-38 glucuronidation rates were reported as the ratios between SN-38 glucuronide (SN-38G) and internal standard (IS) peak heights. The intra-assay variability was determined by performing 10 incubations on the same day using a pool of human liver microsomes. The inter-assay variability was evaluated by incubating a pool of human liver microsomes in triplicate on three different days. The inter-and intraassay variabilities were within 7%.
Statistical analysis
The significance of linkage disequilibrium between pairs of polymorphic sites was assessed using genotypic data and a likelihood ratio test provided in ARLE-QUIN, version 2 [17] . ARLEQUIN was also used to run a modified Markov-chain random walk algorithm to test for Hardy-Weinberg equilibrium. Next, multisite haplotypes were estimated using the program PHASE [18] . Because this program does not accept both biallelic and multi-allelic polymorphic sites, haplotypes
Phenobarbital-responsive enhancer module (PBREM) and description of mutations. The previously described PBREM domains are underlined with the NR half-site sequences shown in bold. The polymorphic sites found in this study are shaded in gray. The variants found at these sites are also listed. Positions indicated are from the first base of the UGT1A1 start site in the UGT1A cluster sequence (AF297093).
were estimated only for individuals with either the (TA) 6 or (TA) 7 alleles.
Thirteen individuals were heterozygous for the (TA) 5 or (TA) 8 repeat, three of which were heterozygous only at the TA repeat and therefore unambiguous at the other sites. For the remaining 10 individuals, haplotypes were determined manually by assuming that the chromosome with the (TA) 6 or (TA) 7 allele contained a haplotype previously identified by the PHASE analysis. In one case, this method would have resulted in a new (TA) 8 haplotype. However, it is more likely that this individual would instead have a novel (TA) 6 haplotype (V), which is consistent with the observation that the (TA) 6 allele is found on multiple haplotypes, including other rare ones. An incorrect assignment would have little or no affect on the subsequent analyses because the novel haplotype only occurs once out of 103 individuals and not in a sample used in studies of correlation with phenotype.
The effective number of haplotypes was calculated as the reciprocal of the sum of the frequency squared. Diversity in (TA) 6 haplotypes in Caucasians and African-Americans, based on the numbers and frequencies of haplotypes and adjusted by sample size, was estimated by DnaSP version 3.53 [19] as well as their SDs. Statistical significance was assessed using a t-test as previously described [20] . The chi-square test was used to analyse the differences in genotype/haplotype frequencies between Caucasians and African-Americans. UGT1A1 activity was phenotyped by measuring SN-38 glucuronidation rates of each liver as the mean AE SD of a single experiment performed in triplicate. The statistical analysis of the relationship between the (TA) n polymorphism and phenotype was planned to assess first the genotype effect on phenotype in the population sample (n ¼ 83) using the analysis of variance (ANOVA). If the genotype effect was statistically significant then, within each ethnic group, a test of trend across the genotypes was performed using the exact Jonkheerer-Terpstra (JT) test [21] . Pairwise comparisons between two genotypes were performed using an exact one-sided Wilcoxon test. Moreover, trend analysis and pairwise comparisons were performed in genotypes expressed as the sum of TA repeats in both chromosomes [i.e. in samples with < 12 (5/6, 6/6, 5/7), 13 (6/7) and > 14 (7/7, 6/8, 7/8) TA repeat genotypes]. Concerning the haplotype-phenotype relationship, two-sided exact Wilcoxon tests were used to compare the SN-38 glucuronidation rates between two haplotypes. SAS system (SAS Institute, Inc., Cary, North Carolina) and StatXact-5 (CYTEL Software Corporation, Cambridge, Massachusetts, USA) were used for statistical analysis. GraphPad software version 3.02 (GraphPad Software Inc., San Diego, California, USA) was used for graphical analysis.
Results
The (TA) 6 allele was the most common allele with a frequency of 0.58 while the (TA) 7 allele had a frequency of 0.36 (Table 1 ). (TA) 5 and (TA) 8 alleles were also found, although at lower frequencies (0.02 and 0.05, respectively). In the population sample (n ¼ 107), the most common genotype was 6/7 (0.41), followed by the 6/6 genotype (0.34). Rare genotypes (, 0.02) included 5/6, 5/7 and 5/8 genotypes. The (TA) 6 and (TA) 7 allele frequencies were not significantly different between Caucasians and African-Americans (chi-square test, P ¼ 0.7). Similarly, 6/6, 6/7, and 7/7 genotype frequencies were not different between the two ethnic groups (chi-square test, P ¼ 0.8). One Asian individual had a 6/6 genotype, while two individuals with other ethnicities had 6/7 and 7/7 genotypes.
Sequencing of PBREM
In 103 samples, six polymorphisms were found, and two of them (À3279G.T and À3156G.A) are common, with frequencies of 0.39 and 0.30, respectively (Fig. 1, Table 2 ). All six polymorphisms are in HardyWeinberg equilibrium (P . 0.5). Based upon comparisons to the baboon sequence (accession number AC091778), it is likely that À3279G and À3156G are the ancestral states. The most common À3279G.T polymorphism is located in the spacer sequence of the NR3 domain of PBREM (Fig. 1) . No variants were found in the gtNR1 domain, the binding site for constitutive active receptor (CAR). À3279G was significantly more common among African-Americans compared to Caucasians (chi squared ¼ 13.82, P ¼ 0.001) while the frequency of À3156A did not significantly differ between the two ethnic groups (chi-square test, P ¼ 0.9). A likelihood ratio test detected significant pairwise linkage disequilibrium between sites À3279, À3156 and the (TA) n polymorphism in our population sample (n ¼ 103, P , 0.0001). When only the common (TA) 6 and (TA) 7 alleles were used for the linkage disequilibrium analysis, the same results were obtained (P , 0.0001). When pairwise linkage disequilibrium was separately assessed in Caucasians and AfricanAmericans, highly significant linkage disequilibrium was similarly detected in Caucasians (P , 0.0001). In African-Americans, pairwise linkage disequilibrium was also detected between all sites, however, the level of significance varied greatly between the pairwise comparisons. Only linkage disequilibrium between (TA) n and À3156 had significance levels similar to those seen for Caucasians (P , 0.0005) while linkage disequilibrium had only low levels of significance between (TA) n and À3279 (P ¼ 0.02) and between À3279 and À3156 (P ¼ 0.04).
Multisite haplotype inference resulted in 10 haplotypes spanning the PBREM variants and the (TA) n polymorphism (Table 3) . Haplotypes I-V include the (TA) 6 allele, and haplotype I differs from haplotype II at position À3279 in the NR3 domain of PBREM. Haplotypes VI, VII and VIII include the (TA) 7 repeat and haplotypes VI and VII differ from each other at position À3156. There is a suggestion that the haplotype structure of the (TA) 6 (Table  3) . Finally, diversity (AE SD) of (TA) 6 haplotypes was 0.555 AE 0.070 and 0.262 AE 0.065 in African-Americans and Caucasians, respectively (P , 0.05).
UGT1A1 phenotyping and association with (TA) n polymorphism and haplotypes UGT1A1 activity was measured as SN-38 glucuronidation rates in 83 human liver microsomes. A 46% coefficient of variation (1.90 AE 0.87 SN-38G/IS, mean AE SD) and a 10-fold range in SN-38 glucuronidation were observed.
Because of the small number of subjects in the 5/7, 5/6, 6/8 and 7/8 genotypes, only 6/6, 6/7 and 7/7 were used in the ANOVA analysis. The phenotype was significantly different across these three genotypes (P ¼ (Fig. 2a) . The degree of variation of the SN-38 glucuronidation rate across the genotypes was similar in different ethnic groups (P . 0.1). A significantly decreasing trend was shown across the 6/6, 6/7 and 7/7 genotypes in Caucasians (P , 0.001, JT test, Fig. 2b ) and across the 6/6, 6/7, 6/8 and 7/7 genotypes in African-Americans (P ¼ 0.033, JT test) (Fig. 2c) . When samples with Asian (n ¼ 1), other (n ¼ 2) and unknown (n ¼ 10) ethnic background were pooled together, no significant trend could be found across (TA) n genotypes (P . 0.1, JT test) (Fig. 2d) . In the Caucasian sample, pairwise comparisons of the phenotype between two genotype groups showed significant differences between the 6/7 and 7/7 (P ¼ 0.007, one-sided exact Wilcoxon test) and 6/6 and 7/7 groups (P ¼ 0.0002). No pair-wise comparison was significant within AfricanAmericans, probably due to small number of samples of each genotype.
When (TA) n genotypes were regarded as the sum of TA repeat number in both chromosomes [i.e. <12 (5/6, 6/6, 5/7), 13 (6/7) and > 14 (7/7, 6/8, 7/8) genotypes], a significant trend of reduced UGT1A1 activity (P , 0.01) was measured across the three groups (the lowest being the > 14 genotype group) in the whole sample population, in Caucasians, in African-Americans but not in samples with Asian/other/unknown ethnicity (P ¼ 0.66). Pairwise comparisons (one-sided exact Wilcoxon test) showed significantly reduced UGT1A1 activity (P , 0.01) in > 14 compared to 13 and < 12 genotypes, and in 13 compared to < 12 genotypes in the whole sample population and in Caucasians. In African-Americans < 12 genotypes had significantly higher UGT1A1 activity compared to either 13 or > 14 genotypes (P ¼ 0.028 and 0.016, respectively), but UGT1A1 activity was not significantly different between 13 and > 14 genotypes (P ¼ 0.11).
In samples of Caucasian and African origin, SN-38 glucuronidation rate varies significantly across the haplotypes with a decreasing trend (P , 0.0001, JT test) (Fig. 3) . However, this apparent haplotype-phenotype correlation is likely to be due to the effect of the (TA) n polymorphism which is in linkage disequilibrium with the PBREM variants. Hence, we investigated the possible functional effects of the common À3279G.T and À3156G.A variants by comparing the SN-38 glucuronidation rates across genotypes that differed only by the variant being examined. Concerning the À3279G.T variant, SN-38 glucuronidation was reduced in I/II pairs compared to I/I pairs among Caucasians, although without reaching statistical significance (2.06 AE 0.74 versus 2.53 AE 0.82 SN-38G/IS, respectively) (Wilcoxon rank sum test, P ¼ 0.18). Concerning the À3156G.A variant, although SN-38 glucuronidation is slightly reduced in I/VII compared to I/VI pairs, the difference is not statistically significant (Wilcoxon rank sum test, P ¼ 0.64).
Discussion
We describe the haplotype structure of the UGT1A1 promoter in a sample including mainly Caucasians and African-Americans. Ten different haplotypes were inferred, of which four account for 90% of all haplotypes. These four main haplotypes derive from the combination of the (TA) 6 and (TA) 7 alleles with two common polymorphisms in the region spanning the PBREM. The À3279G.T variant was shown to be present also in Asian individuals [9] . In a study by Sugatani et al. [9] , the position of this variant is located at À3263 due to differences in reference sequences used. In addition, we have identified a hitherto unknown À3156G.A change localized 117 bp upstream of the PBREM, as well as other low frequency changes. In the gtNR1 domain, which spans the CAR binding site, no variants were found.
Sugatani et al. [9] have shown that the presence of À3279G was associated with a significant 35% increase in bilirubinemia in Asian patients with Gilbert's syndrome. In our study, no statistical differences were observed when SN-38 glucuronidation rates were compared between I/I and I/II haplotypes (differing at À3279), and the functional significance of the À3279G.T variant requires further testing. In Asians (but not in Caucasians and African-Americans), the À3279G.T variant may be in linkage disequilibrium with another promoter variant reducing UGT1A1 expression, ruling out that the À3279G.T variant is functional. On the other hand, if the À3279G variant is associated with reduced UGT1A1 expression, clinical consequences can become manifest when drugs with narrow therapeutic indexes are used, as in the setting of cancer chemotherapy. Subtle changes in UGT1A1 expression might affect the pharmacodynamics of irinotecan, and this hypothesis will be tested in the context of an ongoing prospective pharmacogenetic trial at University of Chicago [6] . Haplotype II is four-fold more common among African-Americans than Caucasians, and the effect of haplotype II (if any) is more likely to be detected in patients of African origin.
With regards to the function of the new À3156G.A polymorphism, previous investigation of the UGT1A1 promoter region extended up to À3190 bp from the start site, and regions upstream of À1362 bp essential for basal level of transcription were not identified [22, 23] . However, in luciferase assays of promoter fragments, increased transcription was observed in the À2614 bp fragment compared to the À3190 bp fragment [23] , suggesting the existence of regulatory elements (such as those involved in inhibition of gene expression) located between À2614 and À3190 and probably not controlling basal expression. Whether the À3156G.A polymorphism resides within a transcriptional regulatory sequence of the UGT1A1 promoter remains unknown, and deserves further investigation.
Concerning the (TA) n genotype-phenotype relationship in Caucasians (the largest ethnic group in this study), 6/7 genotypes are associated with significantly reduced glucuronidation of SN-38 compared to 6/6 genotypes, which is in agreement with our previous findings in an independent set of liver microsomes, mainly of Caucasian origin [24] . The stratification of phenotypes by ethnicity showed no correlation in samples with Asian/other/unknown ethnicities. The small number of samples, the presence of other genetic variants and different handling of the tissue specimens with unknown ethnicity are likely to be confounding factors. Concerning the rare (TA) 8 allele, the five 6/8 genotypes in the present study were found only in African-Americans and seem to have a phenotypic effect intermediate between that of 6/7 and 7/7 genotypes (Fig. 2a,c Haplotype-phenotype relationship in human livers of Caucasian and African origin (n ¼ 70). Bars show the mean value of SN-38 glucuronidation rates in each group. Only haplotypes with > 2 samples are shown. Black corresponds to 6/6, green to 6/7, blue to 6/8 and red to 7/7 genotypes. levels within normal limits [25] . However, Gilbert's syndrome was diagnosed in a child with 6/8 genotype [26] . Thus, it is still unclear whether the 6/8 genotype might have any clinical consequence.
We found interethnic differences in the linkage disequilibrium among the three common polymorphisms [i.e. À3279G.T, À3156G.A and (TA) n ]. Although linkage disequilibrium extends from the (TA) n polymorphism (À53 from the start site) upstream to the PBREM (À3279), the levels of linkage disequilibrium were highly significant for all sites in Caucasians but only between one pair of sites in African-Americans. These lower levels of significance for the other pairwise comparisons in African-Americans may reflect lower levels of linkage disequilibrium among these sites. For example, considering the two most frequent haplotypes in Caucasians, I and VI, (TA) 6 is found with G at À3156 and T at À3279 while (TA) 7 is found with the alternative alleles at À3156 and À3279. On the other hand, for the two most frequent haplotypes in AfricanAmericans, II and VI, G at À3279 is found with both G and A at À3156 as well as both (TA) 6 and (TA) 7 , indicative of lower linkage disequilibrium between À3279 and the other sites, corresponding to the low significance values. This finding of decreased linkage disequilibrium in the African-American sample is expected given the greater number of haplotypes found at relatively high frequencies in African-Americans, as seen by the higher effective number of haplotypes for this sample compared to Caucasians who have only two predominant haplotypes (Table 3) . Our results are consistent with other studies showing a more rapid decay of linkage disequilibrium with distance in Africans compared to Caucasians [27] . A consequence of the differences in linkage disequilibrium between samples is that the haplotypic structure of the UGT1A1 promoter is likely to vary in different ethnicities. This difference in haplotype structure is also reflected in the greater diversity of the (TA) 6 haplotypes in AfricanAmericans than Caucasians. Interestingly, the haplotype structure determined in this study also sheds light on the evolution of the (TA) n repeat polymorphism. The (TA) 6 and (TA) 7 alleles are found on two distinct major haplotypes, respectively, while the remaining haplotypes differ from the major haplotypes at only one or two sites. This suggests that this repeat is relatively stable and that the two alleles are likely to have originated from single mutation events.
Additional studies are necessary to elucidate the haplotype structure of UGT1A1 promoter in Asians. A number of qualitative and quantitative differences in the distribution of UGT1A1 mutations in Asians have been observed. In Asians, the (TA) 7 allele is two-to threefold less common than in Caucasians [2, 28, 29] . On the other hand, functional missense mutations in exon 1 (211G.A and 686C.A) occur frequently among Asians [3, [30] [31] [32] [33] ]. Due to the increased level of coding region mutations in Asians, further studies in this population should evaluate the existence of linkage disequilibrium in the UGT1A1 promoter and test whether linkage disequilibrium extends up to the exon I polymorphisms.
Association studies using individual polymorphisms do not conclusively distinguish among three possible explanations for the observed phenotypic differences: (i) the surveyed polymorphism is causative; (ii) the surveyed polymorphism is in linkage disequilibrium with the causative polymorphism; or (iii) the surveyed polymorphism interacts with other polymorphisms to cause a phenotypic effect. The increasing availability of polymorphism data coupled with linkage disequilibrium analysis switches the focus of association studies from single mutations to haplotypes. Finding an association between the newly identified UGT1A1 promoter haplotypes is beyond the scope of this study. The assessment of haplotype-phenotype correlations is hampered by the limited sample size of haplotype pairs for each (TA) n genotype. Another limitation is that we cannot control for environmental variables (smoking habit, alcohol intake, previous medications) affecting UGT-1A1 expression in donor livers. Such factors might have a negative impact on association studies with limited sample size.
In conclusion, this study stimulates biochemical research on haplotype constructs to verify the function of different combinations of À3279G.T, À3156G.A, (TA) 6 and (TA) 7 on UGT1A1 expression. Due to their high frequency, these four variants, variously combined in several haplotypes, are highly represented and differently distributed in populations of Caucasian and African-American descent.
